The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions

American Journal of Therapeutics

Volumn 18, Issue 1, 2011, Pages 2-8

  Johnson, Franklin K ^a   Ciric, Sabrina ^b   Boudriau, Sophie ^b   Kisicki, James C ^b   Stauffer, Joseph ^a,c  

^a Alpharma Pharmaceuticals LLC   (United States)

^b MDS Inc   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bioavailability; bioequivalence; morphine; opioid; pharmacokinetics

Indexed keywords

MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG RELEASE; DYSURIA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; IRRITABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; VOMITING; XEROSTOMIA;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FASTING; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NALTREXONE; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 78751642100     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181f05957     Document Type: Article

References (19)

1. American Pain Society. Chronic pain in America: roadblocks to relief. Available at: http://www.ampainsoc. org/links/roadblocks/concluderoad.htm. Accessed April 28, 2010.
2. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006;3:489-497.
3. Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
4. Lipman AG, Jackson KC II. Opioid pharmacotherapy. In: Warfield CA, Bajwa ZH, eds. Principles and Practices of Pain Medicine. 2nd ed. New York, NY: McGraw Hill; 2004: 583-600.
5. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181-186.
6. Wright C IV, Kramer ED, Zalman M-A, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend. 2006; 83(Suppl 1):S68-S76.
7. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Invest Drugs. 2009;18:255-263.
8. Embeda [package insert]. Bristol TN: King Pharmaceuticals Inc; June 2009
9. Gonzalez J, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35:192-213.
10. Katz NP, Sun S, Johnson FK, et al. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11:303-311.
11. Johnson FK, Stark JG, Bieberdorf FA, et al. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther. 2010;32:1149-1164.
12. Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Invest. 2009;29:777-790.
13. Kadian [package insert]. Elizabeth NJ: Actavis Elizabeth LLC; February 2009.
14. Nicholson B, Ross E, Weil A, et al. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended release morphine sulfate capsules. Curr Med Res Opin. 2006;22:539-550.
15. US Department of Health and Human Services. Guidance for industry, E6 good clinical practice: consolidated guidance. Available at: http://www.fda.gov/downloads/ regulatoryinformation/guidances/UCM129515.pdf. Published April 1996. Accessed April 28, 2010.
16. World Medical Association. WMA declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: http://www.wma.net/en/30publi-cations/10policies/b3/index.html. 2000. Accessed April 28, 2010.
17. Christrup L. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41:116-122
18. US Department of Health and Human Services. Guidance for industry: statistical approaches to establishing bioequiv-alence. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070244.pdf. Published January 2001. Accessed April 28, 2010
19. US Department of Health and Human Services. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070124.pdf. Published March 2003. Accessed April 28, 2010.